Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Clinical Lung Cancer · 2026-07 · 27 (6) · 19-26
DOI: 10.1016/j.cllc.2026.05.003 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Lung Cancer, 2026-07. Verfasst von Isadora Mamede und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Federal University of São João del Rei, Divinópolis, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, B7-H1 Antigen. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND The benefit of neoadjuvant or perioperative chemoimmunotherapy in resectable non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression < 1% remains uncertain, as evidence is largely derived from subgroup analyses. We conducted a systematic review and network meta-analysis to compare the efficacy of individual chemoimmunotherapy regimens in this population. PATIENTS AND METHODS Randomized controlled trials enrolling patients with resectable NSCLC and reporting outcomes for the PD-L1 < 1% subgroup were identified through searches of PubMed, Embase, and Cochrane CENTRAL. Event-free survival, overall survival, pathological complete response, and major pathological response were evaluated. A Bayesian random-effects network meta-analysis was performed, with treatment ranking using surface under the cumulative ranking curve. RESULTS Eight trials comprising 3387 patients were included, of whom 1012 (29.9%) had PD-L1 < 1%. No chemoimmunotherapy regimen significantly improved event-free survival or overall survival compared with chemotherapy alone. Nivolumab plus chemotherapy was the only regimen associated with a statistically significant improvement in pathological complete response versus chemotherapy (odds ratio 5.88; 95% credible interval 1.41-37.4). No regimen significantly improved major pathological response. Despite the absence of statistically significant survival differences, chemotherapy alone consistently ranked lowest across event-free survival, overall survival, pathological complete response, and major pathological response. CONCLUSION In resectable NSCLC with PD-L1 < 1%, chemoimmunotherapy improves pathological response but has not yet demonstrated a survival benefit. Among available regimens, nivolumab plus chemotherapy shows the most consistent evidence for enhanced pathological response, although current data do not support the superiority of any single immunotherapy strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Federal University of São João del Rei, Divinópolis, Brazil.
- Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ.
- Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
- Faculty of Medicine, Dhaka Medical College and Hospital, Dhaka, Bangladesh.
- Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Phoenix, AZ. Electronic address: Ernani.Vinicius@mayo.edu.
Zitieren
APA
Mamede, I., Taylor, S., Nohmi, R. L., Riya, I. J., Piya, I. J., Hazim, A., & Ernani, V. (2026). Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Clinical Lung Cancer, 27(6), 19-26. https://doi.org/10.1016/j.cllc.2026.05.003
Vancouver
Mamede I, Taylor S, Nohmi RL, Riya IJ, Piya IJ, Hazim A, et al. Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Clinical Lung Cancer. 2026;27(6):19-26. doi:10.1016/j.cllc.2026.05.003
BibTeX
@article{Mamede2026,
author = {Mamede, Isadora and Taylor, Skyler and Nohmi, Rafael Lara and Riya, Israt Jahan and Piya, Ifrat Jahan and Hazim, Antonious and Ernani, Vinicius},
title = {Neoadjuvant Chemoimmunotherapy in Resectable NSCLC With PD-L1 Expression < 1%: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {6},
pages = {19--26},
doi = {10.1016/j.cllc.2026.05.003}
}
EUVIMED